The Chief Medical Officer role in biotech has undergone a structural transformation over the past decade. In 2015, the CMO at a clinical-stage biotech was primarily a medical monitor — an MD who reviewed clinical protocols, managed investigator relationships, and served as the company’s medical face to the FDA. By 2025, the CMO at a comparable company is a strategic executive who sits at the intersection of clinical development, regulatory strategy, commercial planning, and investor relations, with direct influence on pipeline prioritization, trial design, and the company’s public market narrative.
The demand numbers reflect the scope expansion: open CMO positions in US biotech grew from approximately 400 in 2018 to over 2,100 by 2024, driven by the surge in clinical-stage companies funded during the 2020-2022 biotech capital cycle. Compensation has followed: total CMO packages at clinical-stage biotechs now range from $400,000 to $800,000+ in base and bonus, with pre-IPO equity grants that can represent 0.5% to 1.5% of fully diluted shares at Series B and C companies.
What the biotech CMO owns
The modern biotech CMO’s mandate extends well beyond traditional clinical oversight. The scope varies by company stage and therapeutic complexity, but the common definition that has emerged across clinical-stage biotechs includes: clinical development strategy (trial design, endpoint selection, adaptive trial methodology), regulatory interactions (FDA pre-IND meetings, end-of-Phase-2 meetings, advisory committee preparation), medical affairs (KOL engagement, medical education, publication strategy), pharmacovigilance and safety oversight, and increasingly, commercial medical strategy (payer evidence generation, health economics data, market access clinical positioning).
At companies with fewer than 200 employees — which describes the majority of US clinical-stage biotechs — the CMO is often the most senior medical voice in the organization and serves as the primary interface between the company and its clinical investigators, regulatory agencies, and the broader medical community. This concentration of medical authority gives the CMO outsized influence relative to their peer C-suite executives but also creates single-point-of-failure risk that boards and investors are increasingly conscious of.
The key distinction between the CMO and the VP of Clinical Development, in companies that have both: the CMO owns the medical strategy — which indications to pursue, which endpoints will be most convincing to regulators and payers, how to position the clinical data narrative — while the VP of Clinical Development owns the operational execution of trials: site selection, enrollment, CRO management, data monitoring. The two roles are complementary but distinct, and the failure to clarify the boundary between them is one of the more common sources of organizational friction in clinical-stage companies.
CMO compensation in 2025
CMO compensation varies dramatically by company stage, therapeutic area, and whether the company is pre-revenue or commercial. The ranges below reflect our 2024-2025 placement data across approximately 85 CMO searches:
- Pre-clinical / Series A biotech: Base $320K-$380K, bonus 30-40%, equity 1.0-1.5% fully diluted. Total cash comp $416K-$532K
- Clinical-stage / Series B-C biotech: Base $400K-$500K, bonus 35-45%, equity 0.5-1.0% fully diluted. Total cash comp $540K-$725K
- Late-stage / pre-IPO biotech: Base $450K-$550K, bonus 40-50%, equity 0.3-0.6% fully diluted. Total cash comp $630K-$825K
- Commercial-stage biotech (post-approval): Base $500K-$650K, bonus 45-55%, equity via RSUs/options at public company valuations. Total cash comp $725K-$1M
- Large pharma ($10B+ revenue): Base $550K-$750K, bonus 50-70%, LTI 200-400% of base. Total comp $1.1M-$2.5M
The most pronounced compensation gap in the CMO market is between clinical-stage biotech CMOs and large pharma CMOs. A CMO at a Series B oncology biotech with 40 employees might earn $480K in base salary; their counterpart at a top-20 pharma company earns $700K+ with substantially richer benefits, retirement contributions, and deferred compensation. The delta is justified by equity upside: a CMO who joins a clinical-stage biotech at 0.8% fully diluted and sees the company through a successful Phase III readout and IPO can realize $3M to $15M+ in equity value. The risk-adjusted expected value depends entirely on the probability of clinical success, which varies from roughly 60% for late-stage programs to under 10% for early-stage oncology assets.
MD vs PhD CMOs
The MD-versus-PhD debate in CMO hiring has evolved substantially. In the early 2010s, the assumption was that a CMO required an MD — someone who could credibly discuss clinical medicine with investigators, review adverse event profiles with clinical judgment, and represent the company’s medical perspective to FDA advisory committees. This assumption has eroded as the CMO role has become more strategic and less operationally clinical.
Our current data shows that approximately 68% of biotech CMO placements are MDs, 22% are MD-PhDs, and 10% are PhDs with extensive clinical development experience. The PhD CMOs are concentrated in specific therapeutic areas — gene therapy, cell therapy, and rare disease — where the scientific complexity of the mechanism is as important to regulatory strategy as the clinical medicine. In oncology, neuroscience, and immunology, the MD credential remains strongly preferred by boards and investors.
Compensation differences between MD and PhD CMOs are modest at clinical-stage companies (roughly 5-8% premium for MDs) but more pronounced at commercial-stage companies and large pharma, where the MD credential commands a 12-18% premium in total compensation. The premium reflects both the broader scope that MDs can credibly cover (including pharmacovigilance oversight and medical affairs leadership) and the signaling value of the MD credential to external stakeholders including investors, regulators, and partner companies.
Big pharma vs startup biotech
The CMO role at a top-20 pharma company and the CMO role at a 50-person clinical-stage biotech share a title and almost nothing else. The differences are structural and consequential for career planning:
Scope of authority. The biotech CMO is typically the sole senior medical executive and has direct authority over all clinical and medical decisions. The pharma CMO sits within a matrix organization where clinical decisions are shared with therapeutic area heads, global medical affairs leaders, commercial teams, and regional medical directors. The pharma CMO’s authority is broader in scope but shallower in depth — they influence many programs rather than controlling a few.
Board interaction. The biotech CMO presents to the board regularly, often quarterly, and has direct relationships with board members including the scientific advisory board. The pharma CMO presents to the board infrequently and operates primarily through the CEO and the head of R&D. For professionals building toward eventual CEO or board-member careers, the biotech CMO path provides substantially more governance exposure.
Career risk. The biotech CMO’s tenure is directly correlated with clinical program outcomes. A Phase III failure can result in the CMO’s departure within 6 months, regardless of whether the failure was attributable to the CMO’s decisions. Average CMO tenure at clinical-stage biotechs is 3.2 years in our data, compared to 5.1 years at large pharma. The risk is compensated by equity upside, but professionals considering the biotech CMO path should plan for the realistic possibility of a shorter tenure than expected.
Reporting structures
CMO reporting structures have shifted notably in recent years. In our 2024 data, 72% of biotech CMOs report directly to the CEO, 18% report to a Chief Scientific Officer or Head of R&D, and 10% have dual reporting to the CEO and the board’s scientific committee. The direct-to-CEO reporting line is strongly correlated with higher compensation (roughly 15% total comp premium) and longer tenure (3.8 years versus 2.7 years for CMOs reporting to the CSO).
The reporting structure matters because it determines the CMO’s influence on pipeline prioritization and capital allocation decisions. A CMO who reports to the CEO participates directly in discussions about which programs to advance, which to deprioritize, and how to allocate clinical development budget across the portfolio. A CMO who reports to the CSO or Head of R&D is more likely to be positioned as a clinical execution leader whose input on strategic portfolio decisions is mediated through their manager.
For CMO candidates evaluating opportunities, the reporting structure question should be asked directly and early in the interview process. Companies that are genuinely seeking a strategic CMO will be transparent about the CEO reporting line; companies that position the role as reporting to a CSO are often seeking a clinical execution leader with a CMO title, which is a meaningfully different role with different career implications.
Final thoughts
The CMO role in biotech represents one of the most consequential and highest-risk executive positions in the life sciences industry. The combination of scientific depth, regulatory expertise, clinical judgment, and strategic influence required to succeed makes the CMO search one of the more complex executive placements we run. For MD and PhD professionals considering the CMO path, the career calculation involves a genuine trade-off between the financial security and organizational resources of large pharma and the equity upside, scope of authority, and career acceleration potential of clinical-stage biotech.
For current context on how CMO compensation compares to other C-suite roles in life sciences, see our biotech equity compensation guide. For professionals evaluating CMO opportunities at companies where pipeline risk is a central concern, our analysis of C-suite turnover in pharma and biotech provides relevant context on tenure patterns and departure triggers.